Advertisement
All abstracts are currently available online athttp://www.abstracts2view.com/hem07, and will appear in the November 16, 2007issue of Blood, The Journal of The American Society of Hematology.
Advertisement
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through thediscovery, development and commercialization of novel drugs for acutecardiovascular disease, cancer and other debilitating medical conditions.Nuvelo's development pipeline includes alfimeprase, a direct actingfibrinolytic in Phase 2 clinical development for the treatment ofthrombotic-related disorders including acute ischemic stroke and catheterocclusion; and preclinical candidates NU206 for the potential treatment ofchemotherapy/radiation therapy-induced mucositis and inflammatory boweldisease and NU172, a direct thrombin inhibitor for use as a potentialshort-acting anticoagulant during medical or surgical procedures. In addition,Nuvelo expects to continue its research programs in leukemia therapeuticantibodies and Wnt signaling pathway therapeutics to further expand itspipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website athttp://www.nuvelo.com or by phoning 650-517-8000.
This press release contains "forward-looking statements," which includestatements regarding the timing and progress of Nuvelo's clinical stage andresearch programs, the potential benefits that patients may experience fromthe use of our clinical stage compounds, which statements are herebyidentified as "forward-looking statements" for purposes of the safe harborprovided by the Private Securities Litigation Reform Act of 1995. Suchstatements are based on our management's current expectations and involverisks and uncertainties. Actual results and performance could differmaterially from those projected in the forward-looking statements as a resultof many factors, including, without limitation, uncertainties relating to drugdiscovery; clinical development processes; enrollment rates for patients inour clinical trials; changes in relationships with strategic partners anddependence upon strategic partners for the performance of critical activitiesunder collaborative agreements; stock market conditions; the impact ofcompetitive products and technological changes; and uncertainties relating toour ability to obtain funding. These and other factors are identified anddescribed in more detail in Nuvelo's filings with the SEC, including withoutlimitation Nuvelo's quarterly report on Form 10Q for the quarter endedSeptember 30, 2007 and subsequent filings. We disclaim any intent orobligation to update these forward-looking statements.The presentation details are as follows: Date/Time: Saturday, December 8, 2007, 5:30 p.m. ET Poster Session (1792): IREM-1 Is a Cell Surface Receptor Expressed in AML Blasts: Potential for Targeted Immunotherapy in AML Date/Time: Saturday, December 8, 2007, 5:30 p.m. ET Poster Session (923): rNAPc2, a Novel Inhibitor of Tissue Factor/Factor VIIa Complex, Inhibits Tumor Growth and Metastasis in Mouse Models of Colorectal Cancer Date/Time: Sunday, December 9, 2007, 6:00 p.m. ET Poster Session (1866): Safety and Efficacy of Alfimeprase in Subjects with Occluded Central Venous Access Devices: The SONOMA-2 Study Date/Time: Mo
